profit from every $100 of sales.
$0$100
HeartSciences
$0.07-39.09% today
-8.3% in 1 year
1-year low $0.041-year high $0.14
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
HeartSciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| HeartSciences | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads HeartSciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 2.3×
- 482.5×
- –
- 442.6×
- -3,123.5%
- -139.0%
- 0.0%
Profitability
- -1,060.2%
- -89,939.6%
- -97,881.0%
- -88,318.7%
- -119.6%
- -1,086.1%
- -333.4%
- -112.3%
- -237.3%
- 7,396,796.9%
Growth
- −35.8%
- –
- −20.1%
- –
- +130.7%
Financial health
- 443.2×
- 1.46
- 51.2%
- -11.1×
- 1.00
- -152.97
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 868
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 16, 2026 | -0.71 | -0.88 | +19.3% |
| Dec 15, 2025 | -845.45 | -1.28 | −66,209.8% |
| Sep 11, 2025 | -1,576.48 | -1.88 | −83,979.0% |
| Dec 16, 2024 | -0.00 | -2.34 | +99.9% |
| Sep 12, 2024 | -2.64 | -2.31 | −14.4% |
| Jul 29, 2024 | -2.73 | -3.50 | +22.0% |
| Mar 14, 2024 | -0.03 | -6.00 | +99.5% |
| Dec 14, 2023 | -0.16 | -12.00 | +98.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/5Passes 0 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
25No pass
Philip Fisher
–Not enough data
Peter Lynch
21No pass
Joel Greenblatt
–Not enough data
Charlie Munger
32No pass
Terry Smith
25No pass
Questions about HeartSciences
Is HeartSciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the HeartSciences AI analysis
What does HeartSciences do?
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. It is in Medical - Devices.
Does HeartSciences pay a dividend?
No. HeartSciences does not pay a dividend at the moment.
How has HeartSciences stock done over the past year?
Down 8.3% over the past twelve months, to $0.07. It traded between $0.04 and $0.14 and is 53.4% below its high.
Who are HeartSciences's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with HeartSciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.